The filing is a standard disclosure of a poster presentation at a medical congress. No new quantitative data were provided. Monitor for future detailed clinical readouts or regulatory updates on ragistomig.
Price Chart
Executive Summary
NovaBridge Biosciences reported that clinical data from the ongoing Phase 1 trial of ragistomig (ABL503/TJ-L14B), a PD-L1 x 4-1BB bispecific antibody, were presented at the ESMO 2026 Congress. The filing is a routine 6-K disclosure of a scientific poster presentation with no new efficacy, safety, or financial data disclosed.
Key Facts
- Clinical data from the Phase 1 trial of ragistomig (ABL503/TJ-L14B) were presented at ESMO 2026 in Madrid on October 23, 2026.
- Ragistomig is a bispecific antibody targeting PD-L1 and 4-1BB, jointly developed with ABL Bio Inc.
- The filing incorporates the 6-K by reference into several existing registration statements (F-3 and S-8).
- No new financial, safety, or efficacy data were disclosed in the filing text.
Financial Impact
No financial figures disclosed; the filing is a routine clinical data presentation notice.
Risk Factors
- Phase 1 data may not demonstrate sufficient efficacy or safety for advancement.
- Competition in the PD-L1/4-1BB bispecific space is intense.
- No disclosed financial or operational milestones in this filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-429548 |
| Document: 0001193125-26-429548-index-headers.html | 0001193125-26-429548 |
| Document: 0001193125-26-429548-index.html | 0001193125-26-429548 |
| Document: 0001193125-26-429548.txt | 0001193125-26-429548 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.49 | awaiting T+5 | — | $1.25 (−15.77%) |
Oct 25, 2026 2d ago | Press Release | $1.42 | awaiting T+5 | — | $1.25 (−11.62%) |
Oct 23, 2026 4d ago | 6-K | $1.37 | awaiting T+5 | — | $1.25 (−8.39%) |
Oct 13, 2026 14d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.25 (−2.71%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.25 (−34.29%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.25 (−29.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers